# Genmab A/S (GMAB.CO) Stock Price

Genmab stock (GMAB.CO): the Copenhagen-based biotechnology company developing antibody therapies; price, chart and technical indicators.

| Fact | Value |
|---|---|
| Price | kr 3,581.00 |
| Change (Nov 10 close) | −2.19% |
| Observation time | Last price · Nov 10, 2026, 15:59 (UTC) · 2026-11-10T15:59:48Z |
| 52-week range | kr 1,512.00 – kr 3,947.00 (daily closes to November 10, 2026, 248 observations); low on June 3, 2026, high on October 30, 2026 |
| 1Y change | +86.61% (close of November 11, 2025 to close of November 10, 2026) |
| Unit | DKK |
| Symbol | GMAB.CO |
| Exchange | COPENHAGEN |
| Market | Stocks |

## What is Genmab A/S (GMAB.CO)?

Genmab A/S is an international biotechnology company focused on antibody therapeutics for cancer and other serious diseases. It was established in 1999, is headquartered in Copenhagen and has a presence in North America, Europe and Asia Pacific.

Genmab receives royalties from Johnson & Johnson on worldwide sales of DARZALEX, and Kesimpta is marketed by Novartis under a licence from Genmab. EPKINLY (epcoritamab) and Tivdak, developed with Pfizer, are also among the company's products. Genmab completed its tender offer for the Dutch biotechnology company Merus in December 2025, adding Merus's antibody candidate petosemtamab to its pipeline. Genmab's ordinary shares trade on Nasdaq Copenhagen under the code GMAB, and its American depositary shares (ADSs) began trading on the Nasdaq Global Select Market in the United States under the same code in 2019.

Those following Genmab stock usually watch the sales development of the medicines that generate royalties, clinical trial results, approval processes and partnership announcements. On the Lzzo.com Genmab page, the price of the Copenhagen-listed shares appears with its observation time, together with a price history chart and technical indicators.

Sources: genmab.com, ir.genmab.com

## Similar stocks

| Name | Symbol | Last price | Change | Updated (UTC) |
|---|---|---|---|---|
| [Novonesis A/S](https://lzzo.com/stocks/novonesis) | NSIS-B | DKK 440.20 | −3.42% | Nov 10, 15:59 · 2026-11-10T15:59:55Z |
| [Coloplast A/S](https://lzzo.com/stocks/coloplast) | COLO-B | DKK 489.10 | −1.53% | Nov 10, 15:59 · 2026-11-10T15:59:30Z |
| [Ambu A/S](https://lzzo.com/stocks/ambu) | AMBU-B | DKK 86.40 | −0.57% | Nov 10, 15:59 · 2026-11-10T15:59:54Z |
| [Demant A/S](https://lzzo.com/stocks/demant) | DEMANT | DKK 369.00 | −2.07% | Nov 10, 15:59 · 2026-11-10T15:59:47Z |

## Related pages

- [All stocks](https://lzzo.com/stocks)
- [Danish stock market hours](https://lzzo.com/world-stock-markets/trading-hours/denmark)
- [Compare Genmab A/S](https://lzzo.com/compare)
- [Market heatmap](https://lzzo.com/stock-market-heatmap)
- [Data and calculation methods](https://lzzo.com/methodology)

---
Canonical HTML page: https://lzzo.com/stocks/genmab · Not investment advice.